Abstract 1117P
Background
Skin melanoma, particularly acral melanoma, is known for its poor prognosis, often exacerbated by infections and chronic ulcers. Recent research has highlighted the significant role of intratumoral microbiota in various cancers, but its impact remains less understood in Chinese patients with skin melanoma. This study aims to investigate the intratumoral microbiota in melanoma among this group and explore its potential influence on disease progression.
Methods
One hundred melanoma tissue samples from stage III/IV skin or acral melanoma patients at Sun Yat-sen University Cancer Center, collected between 2015 and 2021, were retrospectively collected and underwent LPS immunohistochemistry (IHC). Kaplan-Meier analysis was used to assess the relation of LPS expression and patients overall survival. Microbial diversity was analyzed through 16S rRNA sequencing. Spatial transcriptomics was applied to map LPS-positive and LPS-negative regions, enabling the exploration of transcriptional differences and cell distributions.
Results
Patients with high LPS levels exhibited a median overall survival (mOS) of 13.7 months (95% CI, 10.6–16.9), which was shorter compared to those with low LPS levels, who had not yet reached median survival. Analysis of tumor microbiota revealed significant diversity, with high proportions of Bifidobacterium, Vibrio, Bacillus, Clostridium sensu stricto, and Pseudomonas, among which Pseudomonas was the dominant genus. Spatial transcriptomic analysis of LPS-positive melanoma tissues showed an increased proportion of M2 macrophages and a decreased proportion of effector T cells. Gene set enrichment analysis (GSEA) further indicated the activation of epithelial-mesenchymal transition (EMT) pathways.
Conclusions
High levels of microbiota within melanoma tissues are correlated with poor overall survival and may facilitate tumor immune evasion and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1091P - Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses
Presenter: Danny Rischin
Session: Poster session 04
1092P - Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047
Presenter: Dirk Schadendorf
Session: Poster session 04
1093P - Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma
Presenter: Paolo Ascierto
Session: Poster session 04
1094P - NeoRisk: Neoadjuvant immunotherapy (NeoIT) recurrence risk assessment tool
Presenter: Ines Pires da Silva
Session: Poster session 04
1095P - Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Presenter: Alexander Eggermont
Session: Poster session 04
1096P - Camrelizumab plus apatinib in patients with advanced mucosal melanoma: A 3-year survival update with biomarker analysis
Presenter: Zhengyun Zou
Session: Poster session 04
1098P - Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial
Presenter: Ryan Sullivan
Session: Poster session 04
1099P - COMBI-EU: Adverse event management of adjuvant dabrafenib plus trametinib (D+T) in patients with BRAF V600-mutant melanoma
Presenter: Peter Mohr
Session: Poster session 04
1100P - Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis
Presenter: Igor Samoylenko
Session: Poster session 04